Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Cannabics Pharmaceuticals Inc (CNBX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K N/A
  • Shares Outstanding, K N/A
  • Annual Sales, $ 0 K
  • Annual Income, $ 0 K
  • 60-Month Beta N/A
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 6.37
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm N/A
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date N/A
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.2754 +0.44%
on 06/17/19
0.3590 -22.95%
on 06/05/19
-0.0384 (-12.19%)
since 05/17/19
3-Month
0.2754 +0.44%
on 06/17/19
0.4100 -32.54%
on 03/20/19
-0.1179 (-29.89%)
since 03/15/19
52-Week
0.2710 +2.07%
on 12/28/18
1.3500 -79.51%
on 09/17/18
-0.6984 (-71.63%)
since 06/15/18

Most Recent Stories

More News
Cannabics Pharmaceuticals to Participate at the 9th Annual LD Micro Invitational in Bel Air, California

TEL AVIV, Israel and BETHESDA, Maryland , May 30, 2019 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side...

CNBX : 0.2754 (-5.88%)
Cannabics Pharmaceuticals to Participate at the 9th Annual LD Micro Invitational in Bel Air, California

Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, today announced that it will be presenting at the 9th annual LD Micro...

CNBX : 0.2754 (-5.88%)
Cannabics Pharmaceuticals Announces Initiation of a Nationwide Clinical Study to Evaluate Antitumor Properties of Cannabinoid Compounds on Primary Cancer Biopsies

TEL AVIV , Israel and BETHESDA, Maryland , April 17, 2019 /PRNewswire/ -- Cannabics Pharmaceuticals Inc.   (OTCQB: CNBX), a leader in personalized cannabinoid medicine focused...

CNBX : 0.2754 (-5.88%)
Cannabics Pharmaceuticals Announces Initiation of a Nationwide Clinical Study to Evaluate Antitumor Properties of Cannabinoid Compounds on Primary Cancer Biopsies

Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, today announced that it has obtained approval for a nationwide Israeli...

CNBX : 0.2754 (-5.88%)
OTC Markets Group Announces Gold Sponsorship of 31st Annual ROTH Conference

OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for 10,000 U.S. and global securities, today unveiled the list of OTCQX® Best Market and OTCQB® Venture Market company presentations...

EVLLF : 0.7200 (-1.09%)
TRLFF : 0.3300 (+3.84%)
AITB : 5.37 (+3.27%)
BICXD : 4.5400 (-9.02%)
MMNFF : 2.0600 (+3.26%)
ATEA : 5.6900 (+0.53%)
CWBHF : 11.7452 (+6.20%)
CVSI : 4.2160 (+0.38%)
DUOT : 0.8500 (unch)
CRLBF : 10.1900 (+12.35%)
ARREF : 0.4800 (-2.83%)
CLOK : 0.9590 (-0.10%)
MLCPF : 3.5200 (+11.47%)
CNBX : 0.2754 (-5.88%)
HEOFF : 0.9490 (-1.61%)
MJARF : 0.8850 (-5.39%)
ALEAF : 0.9550 (-1.21%)
OTCM : 31.1500 (+0.48%)
NUPMF : 1.5900 (+0.63%)
GLDLF : 0.6770 (+1.59%)
NMUS : 0.6500 (-9.52%)
NLST : 0.3257 (+1.78%)
GBPT : 0.3000 (+5.93%)
IMLFF : 0.2590 (-1.89%)
KSHB : 4.3905 (-1.11%)
CORVF : 1.6000 (+4.30%)
ELLXF : 2.7400 (+7.03%)
RSSS : 2.3000 (-4.17%)
ISYRF : 0.9150 (+4.21%)
FLUX : 1.0900 (unch)
NWGI : 0.3100 (+3.33%)
QBIO : 1.3000 (unch)
WIZD : 0.1600 (unch)
MRMD : 2.0500 (+1.49%)
GRWG : 3.1300 (+3.64%)
BRTI : 0.1590 (-0.63%)
GTBP : 0.2799 (-2.13%)
MRIC : 3.1100 (-2.81%)
DYAI : 6.10 (+3.39%)
GTBIF : 10.3000 (+5.32%)
MTAFF : 0.8000 (+0.72%)
EMHTF : 2.0305 (-5.12%)
ITHUF : 3.3500 (+6.69%)
ALYE : 3.5000 (-12.50%)
VTLR : 0.1400 (unch)
ARHH : 1.3300 (-0.75%)
OWCP : 0.0150 (-3.85%)
STLHF : 0.5800 (+3.00%)
PPCB : 0.0070 (-4.11%)
ARTH : 0.3250 (+1.56%)
ACRGF : 18.7050 (-0.23%)
Cannabics Pharmaceuticals Closes Agreement With Wize Pharma

Cannabics Pharmaceuticals Inc. (OTCQB: CNBX) a world leader in personalized cannabinoid medicine focused on cancer and its side effects, today announced that it has closed an agreement with Wize Pharma,...

WIZP : 0.5600 (+14.29%)
CNBX : 0.2754 (-5.88%)
Cannabics Pharmaceuticals Closes Agreement With Wize Pharma

BETHESDA, Maryland and TEL AVIV, Israel, March 6, 2019 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB: CNBX) a world leader in personalized cannabinoid medicine focused on cancer and its...

WIZP : 0.5600 (+14.29%)
CNBX : 0.2754 (-5.88%)
Wize Pharma, Inc. Closes Deal to Launch Joint Venture With Cannabics

Wize Pharma, Inc. ("Wize Pharma" or the "Company") (OTCQB: WIZP) a clinical-stage biopharmaceutical company focused on the treatment of ophthalmic disorders, today announced that the Company closed a deal...

WIZP : 0.5600 (+14.29%)
CNBX : 0.2754 (-5.88%)
Wize Pharma, Inc. Closes Deal to Launch Joint Venture With Cannabics

WIZP : 0.5600 (+14.29%)
CNBX : 0.2754 (-5.88%)
Cannabics Pharmaceuticals Submits Protocol for an Ex-Vivo Clinical Study on Biopsies and Cannabinoids

Cannabics Pharmaceuticals Inc. (OTCQB:CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, today announced that it has submitted a protocol for the Helsinki Committee...

CNBX : 0.2754 (-5.88%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Maximum. Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Trade CNBX with:

Key Turning Points

2nd Resistance Point 0.3359
1st Resistance Point 0.3143
Last Price 0.2754
1st Support Level 0.2805
2nd Support Level 0.2683

See More

52-Week High 1.3500
Fibonacci 61.8% 0.9378
Fibonacci 50% 0.8105
Fibonacci 38.2% 0.6832
Last Price 0.2754
52-Week Low 0.2710

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar